Effect of cyclosporine on reperfusion injury in acute myocardial infarction.

By C. Piot, P. Croisille, P. Staat, H. Thibault, G. Rioufol, N. Mewton, R. Elbelghiti, T. Cung, E. Bonnefoy, D. Angoulvant and 11 more. New England Journal of Medicine, 2008

1,362 citations recorded by the source corpus.

Subfields: Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging, Surgery

View Paper: https://www.semanticscholar.org/paper/ffcd2bf6ad8763956fc1015dd4610124bf213732

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pathology and Forensic Medicine

1. Douglas R. Green
2. G. Heusch
3. P. Boya
4. M. Karin
5. Guido Kroemer
6. M. V. Vander Heiden
7. H. Eltzschig
8. J. Lemasters

In Radiology, Nuclear Medicine and Imaging

1. B. Turk
2. Guido Kroemer
3. C. López‐Otín
4. Michael O. Hengartner
5. A. Strasser
6. Eyal Gottlieb
7. Gabriel A. Rabinovich
8. Ralph J. Deberardinis

In Surgery

1. J. Cubillos-Ruiz
2. Ralph J. Deberardinis
3. Beth Levine
4. M. V. Vander Heiden
5. G. Núñez
6. Guido Kroemer
7. Karen H. Vousden
8. Brent R. Stockwell

Citations in the corpus

• Pathophysiology of Myocardial Infarction (2015, positive): “Small clinical studies using cyclosporine in patients with acute myocardial infarction reduced the size of the infarct (250,289).”
• Mitochondrial function as a therapeutic target in heart failure (2016, neutral): “Clinical studies have failed to demonstrate efficacy in most 188,189 , but not all 190,191 , studies; however, most of these studies focused on reducing acute cardiac ischaemia– reperfusion injury and not in limiting left ventricular dysfunction in HF. Chronic administration of cyclosporin has been…”
• Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 (2018, result): “pleted in 2015 (the CIRCUS trial) failed to confirm previous findings from 2008 [386] on the cardioprotective effects of”
• Myocardial no-reflow in humans. (2009, background): “Of note, yclosporine, which blocks the m-PTP, has been recently hown to reduce infarct size by 20% when administered ntravenously in patients undergoing PPCI (31).”
• Ischemia and reperfusion—from mechanism to translation (2011, background): “In a randomized clinical study of 58 individuals with acute myocardial infarction with ST-segment elevation, treatment with an intravenous bolus of cyclosporine immediately before percutaneous coronary intervention was associated with smaller infarct sizes compared to the saline control ( Table 2”
• Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. (2015, background): “and collaborators who demonstrated IS reduction by an intravenous bolus of cyclosporine A just before reperfusion.(323)”
• Cyclosporine before PCI in Patients with Acute Myocardial Infarction. (2015, positive): “New England Journal of Medicine, Massachusetts Medical Society, 2015, 373 (11), pp.”